<DOC>
	<DOCNO>NCT00119600</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics AMG 114 administer subcutaneously treatment chemotherapy induce anemia subject receive multicycle chemotherapy .</brief_summary>
	<brief_title>A Study AMG 114 Administered Subcutaneous Injection Treatment Anemia Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Part A : Nonmyeloid malignancy receive multicycle chemotherapy Receiving nonplatinum contain chemotherapy At least 6 additional week cyclic cytotoxic chemotherapy plan Part B Part C : Nonmyeloid malignancy receive multicycle chemotherapy At least 12 additional week cyclic cytotoxic chemotherapy plan All Parts : Chemotherapy induce anemia Greater 6 month life expectancy ECOG 02 Adequate renal liver function Chronic myeloid leukemia , AML , ALL , Burkitt 's lymphoma lymphoblastic lymphoma History seizure disorder Primary hematologic disorder could cause anemia , nonmyeloid malignancy Unstable angina , congestive heart failure uncontrolled cardiac arrhythmia Uncontrolled hypertension History pure red cell aplasia Clinically significant inflammatory disease active infection Iron deficiency ANC le 0.8 x 10^9 cells/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Non-myeloid malignancy</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>